Gemtuzumab ozogamicin combined with intensive chemotherapy in acute myeloid leukemia patients relapsing after allogenic stem-cell transplantation

We report the use of fractioned gemtuzumab-ozogamicin associated with high dose chemotherapy in 18 patients. The overall response rate was 72% (13/18) including 7 complete remissions. No death was attributed to treatment toxicity.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 5, 2020 Category: Hematology Authors: Alexis Genthon, Eolia Brissot, Florent Malard, Zoe van de Wyngaert, Agn ès Bonnin, Anne Banet, Zora Marjanovic, Souhila Ikhlef, Simona Lapusan, Simona Sestilli, Elise Corre, Annalisa Paviglianiti, Rosa Adaeva, Fella M.’Hammedi-Bouzina, Myriam Labopin, Tags: Original Study Source Type: research